The production of thymulin by the thymic epithelium is under complex control involving the endocrine system. Experimental models have suggested that prolactin (PRL) and growth hormone (GH) participate in this regulation but this has not been documented in humans. Using a bioassay we measured circulating thymulin levels in patients with hyperprolactinemia (n = 21), acromegaly (n = 15), or both (n = 6). Thymulin was elevated in these three groups of patients compared with normal subjects or with patients with pituitary disease but no excess in PRL or GH. Contrasting with observations in control groups, thymulin did not decrease as a function of age in patients. No correlation between thymulin and PRL or GH levels was observed while thymulin and insulin-like growth factor 1 levels were correlated. A new radioimmunoassay used in some patients for thymulin determination yielded similar results. Overall these data demonstrate that PRL and GH are involved in the hormonal control of thymulin production by the thymic epithelium in the human.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Inflammatory proteins and hidradenitis suppurativa: Insights from genetic correlation and Mendelian randomization.
J Dermatol
December 2024
Department of Traditional Chinese Medicine, People's Hospital of Xiangyun County, Dali, China.
Previous research has highlighted a significant association between inflammatory proteins and the development and progression of hidradenitis suppurativa (HS). Nevertheless, the potential causative link between these factors remains to be definitively established. To investigate the genetic correlation between inflammatory proteins and HS, linkage disequilibrium score regression (LDSC) was employed.
View Article and Find Full Text PDFPeripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner.
Proc Natl Acad Sci U S A
September 2024
Department of Biochemistry, Microbiology and Immunology, Wayne State University Medical School, Detroit, MI 48201.
Identifying tumor-mediated mechanisms that impair immunity is instrumental for the design of new cancer therapies. Regulatory T cells (Tregs) are a key component of cancer-derived immune suppression; however, these lymphocytes are necessary to prevent systemic autoimmunity in mice and humans, and thus, direct targeting of Tregs is not a clinical option for cancer patients. We have previously demonstrated that excising transcription factor Kruppel-like factor 2 () within the T cell lineage blocks the generation of peripheral-derived Tregs (pTregs) without impairing production of thymic-derived Tregs.
View Article and Find Full Text PDFSelectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect.
Acta Pharm Sin B
July 2024
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homing anti-SARS-CoV-2 drug in treating COVID-19 patients.
View Article and Find Full Text PDFComprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation.
Sci Rep
April 2024
Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, USA.
Prurigo nodularis (PN) is a chronic inflammatory skin disease that is associated with variability in peripheral blood eosinophil levels and response to T-helper 2 targeted therapies (Th2). Our objective was to determine whether circulating immune profiles with respect to type 2 inflammation differ by race and peripheral blood eosinophil count. Plasma from 56 PN patients and 13 matched healthy controls was assayed for 54 inflammatory biomarkers.
View Article and Find Full Text PDFctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
Front Oncol
September 2023
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Article Synopsis
- Researchers studied the association of circulating tumor DNA (ctDNA) with recurrence in patients with unresectable non-small cell lung cancer (NSCLC) following definitive radiation therapy, aiming for better disease management.
- A cohort of 17 patients had 70 plasma samples analyzed, revealing an 82% detection rate for ctDNA before treatment; however, only 35% were ctDNA-positive shortly after treatment, all of whom showed clinical progression.
- The findings indicated that ctDNA positivity significantly correlated with worse progression-free survival, suggesting that monitoring ctDNA could facilitate early recurrence detection and help identify patients who may need more aggressive treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!